These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8610774)
21. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Gebara OC; Mittleman MA; Sutherland P; Lipinska I; Matheney T; Xu P; Welty FK; Wilson PW; Levy D; Muller JE Circulation; 1995 Apr; 91(7):1952-8. PubMed ID: 7895352 [TBL] [Abstract][Full Text] [Related]
22. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Sumino H; Ichikawa S; Sawada Y; Sakamoto H; Kumakura H; Takayama Y; Sakamaki T; Kurabayashi M Thromb Res; 2005; 115(5):359-66. PubMed ID: 15733968 [TBL] [Abstract][Full Text] [Related]
23. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]. Winkler UH; Krämer R; Kwee B; Schindler AE Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837 [TBL] [Abstract][Full Text] [Related]
24. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Post MS; van der Mooren MJ; van Baal WM; Blankenstein MA; Merkus HM; Kroeks MV; Franke HR; Kenemans P; Stehouwer CD Am J Obstet Gynecol; 2003 Nov; 189(5):1221-7. PubMed ID: 14634544 [TBL] [Abstract][Full Text] [Related]
25. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Koh KK; Horne MK; Csako G; Waclawiw MA; Cannon RO Am J Cardiol; 1999 Feb; 83(3):466-9, A10. PubMed ID: 10072247 [TBL] [Abstract][Full Text] [Related]
26. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Salobir BG; Keber I; Vrabic L Fertil Steril; 2002 Dec; 78(6):1178-83. PubMed ID: 12477508 [TBL] [Abstract][Full Text] [Related]
27. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ Menopause; 2008; 15(2):248-55. PubMed ID: 17693902 [TBL] [Abstract][Full Text] [Related]
28. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712 [TBL] [Abstract][Full Text] [Related]
29. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. Koh KK Int J Hematol; 2002 Aug; 76 Suppl 2():44-6. PubMed ID: 12430899 [TBL] [Abstract][Full Text] [Related]
31. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Douketis JD; Gordon M; Johnston M; Julian JA; Adachi JR; Ginsberg JS Thromb Res; 2000 Jul; 99(1):25-34. PubMed ID: 11012376 [TBL] [Abstract][Full Text] [Related]
32. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040 [TBL] [Abstract][Full Text] [Related]
33. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753 [TBL] [Abstract][Full Text] [Related]
34. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343 [TBL] [Abstract][Full Text] [Related]
35. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Gebara OC; Mittleman MA; Walsh BW; Lipinska I; Welty FK; Bellotti G; Muller JE; Sacks FK; Tofler GH Heart; 1998 Sep; 80(3):235-9. PubMed ID: 9875081 [TBL] [Abstract][Full Text] [Related]
36. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy]. Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582 [TBL] [Abstract][Full Text] [Related]
37. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Brosnan JF; Sheppard BL; Norris LA Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018 [TBL] [Abstract][Full Text] [Related]
38. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause--influence of hormone replacement therapy. Estellés A; Cano A; Falcó C; España F; Gilabert J; Grancha S; Aznar J Thromb Haemost; 1999 Jan; 81(1):104-10. PubMed ID: 10348700 [TBL] [Abstract][Full Text] [Related]
39. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy]. Ciepłuch R; Czestochowska E Pol Tyg Lek; 1995 Sep; 50(36-39):13-5. PubMed ID: 8650021 [TBL] [Abstract][Full Text] [Related]